NovaScan, a clinical stage oncology company based in Chicago, announced that it has started a human GI clinical trial for its nsCanary™ device at Texas International Endoscopy Center (TIEC), led by Principal Investigator Isaac Raijman MD. This trial will include 200 patients across several clinical areas, including upper and lower gastrointestinal lumen, pancreas and biliary tract. It is anticipated that the trial will collect the data by the Spring of 2023.
